CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
Fluticasone Furoate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01128569
NCT01128569Phase 2Completed
CompareCT.gov

A Randomised, Double-blind, Placebo-controlled, Three-way Crossover, Repeat Dose Pilot Study Comparing the Effect of Inhaled Fluticasone Furoate/GW642444M Combination and Fluticasone Furoate on the Allergen-induced Early Asthmatic Response in Subjects With Mild Asthma

GlaxoSmithKline·interventional·Posted May 24, 2010·Updated Jan 18, 2017

In Brief

A Phase 2 clinical trial evaluating Fluticasone Furoate, FF/Vilanterol (VI; GW642444M), and 1 other intervention for Asthma. Completed, enrolled 52 participants across 4 sites in 3 countries.

Detailed Summary

We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from allergic triggers in asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesGermany, New Zealand, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 24, 2010
Enrollment StartJan 1, 2010
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.1 years ago

Interventions

Fluticasone Furoatedrug

FF

FF/Vilanterol (VI; GW642444M)drug

FF/VI

Placebodrug

Placebo Inhaler